Find policies, billing codes, payers, states, and providers

HCPCS J0879: Injection of difelikefalin for ESRD on Dialysis

HCPCS Level II code J0879 identifies an injection of difelikefalin, 0.1 microgram, for patients with end-stage renal disease receiving dialysis. This code captures administration of a specialty injectable therapy used within the dialysis setting and is relevant to outpatient dialysis centers and hospital outpatient infusion units. Nationally, accurate capture of J0879 affects specialty drug coverage, dialysis bundle accounting, and Medicare and commercial payer reimbursement workflows.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing and coding context for this dialysis-specific injectable, typical sites of service, and the payer landscape that typically covers infusion and injectable therapies in the ESRD population. The publication provides benchmarks and policy-oriented updates relevant to billing practices and reimbursement classification for specialty injectables in dialysis, alongside clinical context needed for correct service-line attribution.

The content is aimed at revenue cycle, dialysis clinic administrators, and policy analysts seeking clear, national-level guidance on how this HCPCS Level II code is used and what to expect from major payers in coverage and claims processing. Data not available in the input is noted where applicable.

Customize your policy alerts

Sign up for hcpcs J0879 policy alerts

Get alerted when payer policies referencing J0879 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

HCPCS Level II code J0879 represents an injection of difelikefalin, dosed at 0.1 microgram, specifically indicated for end-stage renal disease (ESRD) patients on dialysis. This service is a pharmacologic infusion/injectable therapy administered to manage clinical symptoms in the dialysis population.

Service type: Injectable drug administration (renal dialysis population)

Typical site of service: Outpatient dialysis center or hospital outpatient infusion center, reflecting administration during or in conjunction with maintenance dialysis sessions.

Explore openpayer tools

View all tools

Find policies, billing codes, payers, states, and providers

HCPCS J0879: Injection of difelikefalin for ESRD on Dialysis

Customize your policy alerts

Sign up for hcpcs J0879 policy alerts

Get alerted when payer policies referencing J0879 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service type: Injectable drug administration (renal dialysis population)

Typical site of service: Outpatient dialysis center or hospital outpatient infusion center, reflecting administration during or in conjunction with maintenance dialysis sessions.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with end-stage renal disease (ESRD) receiving maintenance hemodialysis who experiences moderate-to-severe chronic pruritus refractory to topical measures and antihistamines. The patient presents to an outpatient dialysis unit on a scheduled dialysis day. The dialysis nurse or dialysis clinic clinician documents persistent itching despite prior conservative treatments and confirms indication for intravenous administration of difelikefalin during the dialysis session. Medication is prepared per facility medication policies, labeled as J0879 (difelikefalin, 0.1 microgram units), and administered intravenously via the dialysis venous access at the prescribed dose and timing relative to the dialysis treatment. Vital signs and any immediate adverse reactions are monitored during and after the injection. Documentation includes the indication (pruritus due to ESRD), dose administered, route, date/time, lot number, and related dialysis session details. Billing is submitted using HCPCS Level II code J0879 with applicable modifier(s) to reflect circumstances such as professional/technical circumstances, partial administration, or supplier billing nuances. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for ESRD dialysis-associated therapy coverage decisions.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/not administered to any patient	Use when part of the vial is wasted and must be reported for accurate inventory and payer requirements.
`JZ`	No drug was wasted; full amount administered	Use when the entire dispensed single-use vial or dose was administered.
`CQ`	Monoclonal antibody or immunotherapy administration by outpatient hospital	Use if billing under outpatient hospital claims when applicable; note may be payer-specific.
`FX`	Primary surgeon economically or medically unrelated procedure	Use when unrelated services are billed by the primary surgeon separate from the difelikefalin administration context (rare for this drug).
`QX`	Service performed by an auxiliary personnel with an assistant at the request of the physician	Use when an assistant (e.g., dialysis RN under supervision) performs the administration per facility policy and payer requires reporting.
`FY`	Drug billed under a pharmacy benefit or when supplied by pharmacy	Use when the drug is billed through the pharmacy benefit rather than medical benefit, per payer rules.
`SH`	Outpatient hospital service provided under a physician’s direction	Use when outpatient hospital staff provide the infusion or injection during dialysis under physician direction.
`62`	Two surgeons	Use only in rare instances if two clinicians share responsibility for the procedure (typically not used for drug administration).
`78`	Unplanned return to operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period	Use only if an unplanned related procedure occurs; seldom applicable for this injection.
`80`	Assistant surgeon	Use only if an assistant surgeon is involved in the procedure; rarely applicable.

Taxonomy Code	Specialty	Notes
`174100000X`	Nephrology	Nephrologists direct ESRD management and order difelikefalin for dialysis-associated pruritus.
`163WH0700X`	Dialysis Facility/Staff (Nursing)	Dialysis nurses administer intravenous medications during dialysis sessions.
`207RC0000X`	Internal Medicine	Hospital-based or clinic internists may manage ESRD patients and prescribe symptomatic therapies.
`207L00000X`	Emergency Medicine	Emergency clinicians may administer or manage adverse reactions if they occur in urgent settings.
`363A00000X`	Pharmacist	Pharmacists prepare and verify dosing, lot numbers, and billing details for `J0879`.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L29.8`	Other pruritus	Common coding for generalized pruritus when associated with ESRD and used as the primary indication for difelikefalin.
`L29.9`	Pruritus, unspecified	Used when the documentation lists pruritus without further specification; applicable for symptomatic treatment.
`N18.6`	End stage renal disease	Primary underlying condition indicating the patient is on dialysis; required to justify dialysis-associated pruritus treatment.
`N18.9`	Chronic kidney disease, unspecified	Used when CKD stage is documented but ESRD status is not explicitly coded; may accompany pruritus coding.
`T78.40XA`	Allergy, unspecified, initial encounter	Used if an allergic reaction to prior therapies is documented and alternative therapy like difelikefalin is provided; applicable when relevant.
`R23.8`	Other skin changes	Used when pruritus is accompanied by visible skin findings during assessment in dialysis patients.
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing pharmacologic therapy management in chronic conditions and to contextualize chronic medication use in ESRD patients.
`Z99.2`	Dependence on renal dialysis	Supports the setting of service and clinical context for administration of `J0879` during dialysis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used when documenting a per-session injectable medication administration code if payer accepts CPT administration codes alongside HCPCS drug code billing; might be used for non-IV routes when applicable.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when a monitored intravenous infusion is provided in addition to the single-dose injection during the dialysis session and the infusion meets time thresholds.
`96361`	Hydration, therapeutic administration (for infusion of fluids), each additional hour	May be used if additional infusion or hydration services are provided during the dialysis encounter separate from the drug injection.
`99211`	Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician	Used to report brief nursing evaluation or monitoring related to medication administration at the dialysis unit when billing a separate E/M for the encounter.
`G0318`	Dialysis procedure with medical evaluation and/or management	Used for dialysis encounters where medication administration occurs during the dialysis session and is reported as part of the dialysis encounter for certain payers; reflects encounter-level services.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single drug	Sometimes used by analogy in infusion centers for billing complex infusion administration when payer requires chemotherapy administration codes; rarely used for single-dose adjunct medications but included when infusion technique coding is needed.

Related Codes

HCPCS-J0013-ESKETAMINE-NASAL-SPRAY-1MG

HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg

HCPCS-J0120-INJECTION-TETRACYCLINE-250MG

HCPCS J0120: Injection, Tetracycline, Up to 250 mg

HCPCS-J0121-OMADACYCLINE-INJECTION-1MG

HCPCS J0121: Omadacycline Injection, 1 mg

HCPCS-J0122-ERAVACYCLINE-INJECTION-1MG

HCPCS J0122: Injection, Eravacycline, 1 mg

HCPCS-J0129-ABATACEPT-INJECTION-10MG-PHYSICIAN-SUPERVISED

HCPCS J0129: Abatacept Injection, 10 mg

HCPCS-J0130-INJECTION-ABCIXIMAB-10MG

HCPCS Level II J0130: Injection abciximab, 10 mg

HCPCS-J0131-INJECTION-ACETAMINOPHEN-10MG-PARENTERAL-ANALGESIC

HCPCS J0131: Injection Acetaminophen, 10 mg

HCPCS-J0132-INJECTION-ACETYLCYSTEINE-100MG-INJECTABLE-MEDICATION

HCPCS J0132: Injection, Acetylcysteine 100 mg

HCPCS-J0133-ACYCLOVIR-INJECTION-5MG

HCPCS J0133: Injection, Acyclovir 5 mg

HCPCS-J0134-ACETAMINOPHEN-INJECTION-FRESENIUS-KABI-10MG

HCPCS J0134: Injection, Acetaminophen (Fresenius Kabi), 10 mg

Showing 1–10 of 991

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/not administered to any patient	Use when part of the vial is wasted and must be reported for accurate inventory and payer requirements.
`JZ`	No drug was wasted; full amount administered	Use when the entire dispensed single-use vial or dose was administered.
`CQ`	Monoclonal antibody or immunotherapy administration by outpatient hospital	Use if billing under outpatient hospital claims when applicable; note may be payer-specific.
`FX`	Primary surgeon economically or medically unrelated procedure	Use when unrelated services are billed by the primary surgeon separate from the difelikefalin administration context (rare for this drug).
`QX`	Service performed by an auxiliary personnel with an assistant at the request of the physician	Use when an assistant (e.g., dialysis RN under supervision) performs the administration per facility policy and payer requires reporting.
`FY`	Drug billed under a pharmacy benefit or when supplied by pharmacy	Use when the drug is billed through the pharmacy benefit rather than medical benefit, per payer rules.
`SH`	Outpatient hospital service provided under a physician’s direction	Use when outpatient hospital staff provide the infusion or injection during dialysis under physician direction.
`62`	Two surgeons	Use only in rare instances if two clinicians share responsibility for the procedure (typically not used for drug administration).
`78`	Unplanned return to operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period	Use only if an unplanned related procedure occurs; seldom applicable for this injection.
`80`	Assistant surgeon	Use only if an assistant surgeon is involved in the procedure; rarely applicable.

Taxonomy Code	Specialty	Notes
`174100000X`	Nephrology	Nephrologists direct ESRD management and order difelikefalin for dialysis-associated pruritus.
`163WH0700X`	Dialysis Facility/Staff (Nursing)	Dialysis nurses administer intravenous medications during dialysis sessions.
`207RC0000X`	Internal Medicine	Hospital-based or clinic internists may manage ESRD patients and prescribe symptomatic therapies.
`207L00000X`	Emergency Medicine	Emergency clinicians may administer or manage adverse reactions if they occur in urgent settings.
`363A00000X`	Pharmacist	Pharmacists prepare and verify dosing, lot numbers, and billing details for `J0879`.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L29.8`	Other pruritus	Common coding for generalized pruritus when associated with ESRD and used as the primary indication for difelikefalin.
`L29.9`	Pruritus, unspecified	Used when the documentation lists pruritus without further specification; applicable for symptomatic treatment.
`N18.6`	End stage renal disease	Primary underlying condition indicating the patient is on dialysis; required to justify dialysis-associated pruritus treatment.
`N18.9`	Chronic kidney disease, unspecified	Used when CKD stage is documented but ESRD status is not explicitly coded; may accompany pruritus coding.
`T78.40XA`	Allergy, unspecified, initial encounter	Used if an allergic reaction to prior therapies is documented and alternative therapy like difelikefalin is provided; applicable when relevant.
`R23.8`	Other skin changes	Used when pruritus is accompanied by visible skin findings during assessment in dialysis patients.
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing pharmacologic therapy management in chronic conditions and to contextualize chronic medication use in ESRD patients.
`Z99.2`	Dependence on renal dialysis	Supports the setting of service and clinical context for administration of `J0879` during dialysis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used when documenting a per-session injectable medication administration code if payer accepts CPT administration codes alongside HCPCS drug code billing; might be used for non-IV routes when applicable.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when a monitored intravenous infusion is provided in addition to the single-dose injection during the dialysis session and the infusion meets time thresholds.
`96361`	Hydration, therapeutic administration (for infusion of fluids), each additional hour	May be used if additional infusion or hydration services are provided during the dialysis encounter separate from the drug injection.
`99211`	Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician	Used to report brief nursing evaluation or monitoring related to medication administration at the dialysis unit when billing a separate E/M for the encounter.
`G0318`	Dialysis procedure with medical evaluation and/or management	Used for dialysis encounters where medication administration occurs during the dialysis session and is reported as part of the dialysis encounter for certain payers; reflects encounter-level services.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single drug	Sometimes used by analogy in infusion centers for billing complex infusion administration when payer requires chemotherapy administration codes; rarely used for single-dose adjunct medications but included when infusion technique coding is needed.

Related Codes

HCPCS-J0013-ESKETAMINE-NASAL-SPRAY-1MG

HCPCS Level II J0013: Esketamine Nasal Spray, 1 mg

HCPCS-J0120-INJECTION-TETRACYCLINE-250MG

HCPCS J0120: Injection, Tetracycline, Up to 250 mg

HCPCS-J0121-OMADACYCLINE-INJECTION-1MG

HCPCS J0121: Omadacycline Injection, 1 mg

HCPCS-J0122-ERAVACYCLINE-INJECTION-1MG

HCPCS J0122: Injection, Eravacycline, 1 mg

HCPCS-J0129-ABATACEPT-INJECTION-10MG-PHYSICIAN-SUPERVISED

HCPCS J0129: Abatacept Injection, 10 mg

HCPCS-J0130-INJECTION-ABCIXIMAB-10MG

HCPCS Level II J0130: Injection abciximab, 10 mg

HCPCS-J0131-INJECTION-ACETAMINOPHEN-10MG-PARENTERAL-ANALGESIC

HCPCS J0131: Injection Acetaminophen, 10 mg

HCPCS-J0132-INJECTION-ACETYLCYSTEINE-100MG-INJECTABLE-MEDICATION

HCPCS J0132: Injection, Acetylcysteine 100 mg

HCPCS-J0133-ACYCLOVIR-INJECTION-5MG

HCPCS J0133: Injection, Acyclovir 5 mg

HCPCS-J0134-ACETAMINOPHEN-INJECTION-FRESENIUS-KABI-10MG

HCPCS J0134: Injection, Acetaminophen (Fresenius Kabi), 10 mg

Showing 1–10 of 991

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.